Search research articles
Contact Us
Filters
Showing results (91-100 of 492) with videos related to
Page
of 50
Sort By:
Nature Reviews. Cancer
|
June 11, 2010
Envisioning the future of early anticancer drug development
Timothy A Yap, Shahneen K Sandhu, Paul Workman, et al.
Current Opinion in Pharmacology
|
July 16, 2008
Targeting CYP17: established and novel approaches in prostate cancer
Timothy A Yap, Craig P Carden, Gerhardt Attard, et al.
European Urology
|
July 20, 2025
Novel Therapeutic Strategies for Metastatic Prostate Cancer Care
Alessia Cimadamore, Cristina Boixareu, Adam Sharp, et al.
Expert Opinion on Drug Discovery
|
March 15, 2013
Targeting cell cycle kinases and kinesins in anticancer drug development
Timothy A Yap, L Rhoda Molife, Sarah P Blagden, et al.
Oncogene
|
May 20, 2014
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects
R Ferraldeschi, J Welti, J Luo, et al.
Expert Opinion on Investigational Drugs
|
July 23, 2011
Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies
Timothy A Yap, David Olmos, Lulama Rhoda Molife, et al.
Journal of Musculoskeletal & Neuronal Interactions
|
March 31, 2007
Influence of birth weight on peripheral bone in young Gambian adults: a pQCT study
S de Bono, M A Laskey, M Ceesay, et al.
BMJ Open
|
November 28, 2022
What is the impact of targeted therapies given within phase I trials on the cognitive function of patients with advanced cancer: a mixed-methods exploratory study conducted in an early clinical trials unit
Sarah Stapleton, Anne-Sophie Emma Darlington, J S de Bono, et al.
Current Opinion in Oncology
|
April 6, 2012
Targeting the DNA damage response in oncology: past, present and future perspectives
Bristi Basu, Timothy A Yap, L Rhoda Molife, et al.
European Urology
|
April 10, 2025
Reply to Felix Melchior, Andreas Pircher, and Isabel Heidegger's Letter to the Editor re: Johann S. de Bono, Meng He, Chen Shi, et al. Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. Eur Urol. 2025;87:468-75
Christopher Sweeney, Meng He, Matthew Wongchenko, et al.
Page
of 50
Search research articles
Search
Showing results (91-100 of 492) with videos related to
Sort By:
Page
of 50
Nature Reviews. Cancer
|
June 11, 2010
Envisioning the future of early anticancer drug development
Timothy A Yap, Shahneen K Sandhu, Paul Workman, et al.
Current Opinion in Pharmacology
|
July 16, 2008
Targeting CYP17: established and novel approaches in prostate cancer
Timothy A Yap, Craig P Carden, Gerhardt Attard, et al.
European Urology
|
July 20, 2025
Novel Therapeutic Strategies for Metastatic Prostate Cancer Care
Alessia Cimadamore, Cristina Boixareu, Adam Sharp, et al.
Expert Opinion on Drug Discovery
|
March 15, 2013
Targeting cell cycle kinases and kinesins in anticancer drug development
Timothy A Yap, L Rhoda Molife, Sarah P Blagden, et al.
Oncogene
|
May 20, 2014
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects
R Ferraldeschi, J Welti, J Luo, et al.
Expert Opinion on Investigational Drugs
|
July 23, 2011
Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies
Timothy A Yap, David Olmos, Lulama Rhoda Molife, et al.
Journal of Musculoskeletal & Neuronal Interactions
|
March 31, 2007
Influence of birth weight on peripheral bone in young Gambian adults: a pQCT study
S de Bono, M A Laskey, M Ceesay, et al.
BMJ Open
|
November 28, 2022
What is the impact of targeted therapies given within phase I trials on the cognitive function of patients with advanced cancer: a mixed-methods exploratory study conducted in an early clinical trials unit
Sarah Stapleton, Anne-Sophie Emma Darlington, J S de Bono, et al.
Current Opinion in Oncology
|
April 6, 2012
Targeting the DNA damage response in oncology: past, present and future perspectives
Bristi Basu, Timothy A Yap, L Rhoda Molife, et al.
European Urology
|
April 10, 2025
Reply to Felix Melchior, Andreas Pircher, and Isabel Heidegger's Letter to the Editor re: Johann S. de Bono, Meng He, Chen Shi, et al. Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. Eur Urol. 2025;87:468-75
Christopher Sweeney, Meng He, Matthew Wongchenko, et al.
Page
of 50